ArticleEuropean journal of medical research2025
Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letrozole Co-Administration in Progestin-Primed Ovarian Stimulation (PPOS) Protocols for Patients Undergoing In Vitro Fertilization: A Systematic Review.Journal of clinical medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFor poor ovarian response patients, obtaining higher number of transferable and high-quality embryos is crucial and progestin-primed ovarian stimulation protocol is becoming widespread and constantly improving in this population. Letrozole has shown promise in numerous protocols and individuals. This study aims to evaluate the effect of the early addition of letrozole in progestin-primed ovarian stimulation protocol among expected poor ovarian response patients.
methodsThis retrospective cohort study was performed in POSEIDON group 3 and 4 patients who underwent in vitro fertilization or intracytoplasmic sperm injection with their first progestin-primed ovarian stimulation protocol from January 1, 2018 to December 31, 2021. Totally 557 patients were enrolled in this research with 189 ovarian stimulation cycles for POSEIDON group 3 patients and 368 ovarian stimulation cycles for POSEIDON group 4 patients. The primary outcome of this study was the cumulative live birth rate and cumulative clinical pregnancy rate, and the second outcomes included the laboratory outcomes and pregnancy outcomes, maternal and neonatal complications also were encompassed.
resultsIn this study, progestin-primed ovarian stimulation protocol combined with letrozole (study group) was associated with a significantly higher number of oocytes for retrieval and maturation [3.0 (2.0, 5.0) vs. 2.0 (1.3, 4.0), P < 0.001; 3.0 (2.0, 5.0) vs. 2.0 (1.0, 3.8), P < 0.001] as well as 2PN embryos [2.0 (1.0, 3.0) vs. 2.0 (1.0, 3.0), P = 0.026] among POSEIDON group 4 patients. In POSEIDON group 3 patients, the letrozole cotreatment did not show an advantage in these indicators. There was no significant difference in both cumulative live birth rate and cumulative clinical pregnancy rate between the study and control group in POSEIDON group 3 and 4 patients. Multivariate logistic regression model showed that significant favorable effects of the number of available embryos on cumulative live birth rate in all included patients.
conclusionsThese findings indicate that advanced-aged poor ovarian response patients may benefit more from using letrozole as an advantageous adjuvant agent in the progestin-primed ovarian stimulation protocol to obtain more oocytes and embryos in clinical practice. Trial registration This trial was retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.